nemolizumab pruritus
Selected indexed studies
- Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. (N Engl J Med, 2020) [PMID:32640132]
- Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence. (J Dermatolog Treat, 2026) [PMID:41504136]
- Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. (J Allergy Clin Immunol, 2020) [PMID:31449914]
_Worker-drafted node — pending editorial review._
Connections
nemolizumab pruritus is a side effect of
Sources
- Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. (2020) pubmed
- Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence. (2026) pubmed
- Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. (2020) pubmed
- Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. (2022) pubmed
- Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series. (2025) pubmed
- Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. (2023) pubmed
- Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. (2024) pubmed
- Nemolizumab for Cholestatic Pruritus in a Patient With Liver Transplant and Primary Sclerosing Cholangitis. (2025) pubmed
- Nemolizumab Improves Pruritus in Patients With Intrinsic Atopic Dermatitis Lacking Atopic Predisposition: A Single-Centre Pilot Retrospective Cohort Study. (2025) pubmed
- Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. (2022) pubmed